Tropicamide
 |
|
| Clinical data | |
|---|---|
| Trade names | Mydriacyl, others |
| AHFS/Drugs.com | Monograph |
| Pregnancy category |
|
| Routes of administration |
topical eye drops |
| ATC code | |
| Pharmacokinetic data | |
| Protein binding | 45% |
| Identifiers | |
|
|
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| ECHA InfoCard | 100.014.673 |
| Chemical and physical data | |
| Formula | C17H20N2O2 |
| Molar mass | 284.353 g/mol |
  (what is this?)
|
|
Tropicamide, sold under the brand name Mydriacyl among others, is a medication used to dilate the pupil and help with examination of the eye. Specifically it is used to help examine the back of the eye. It is applied as eye drops. Effects occur within 40 minutes and lasts for up to a day.
Common side effects include blurry vision, increased intraocular pressure, and sensitivity to light. Another rare but severe side effects is psychosis, particularly in children. It is unclear if use during pregnancy is safe for the baby. Tropicamide is in the antimuscarinic part of the anticholinergic family of medication. It works by making the muscles within the eye unable to respond.
Tropicamide was approved for medical use in the United States in 1960. It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system. The wholesale cost in the developing world is about 4.19 to 4.55 USD per 15 ml bottle. In the United States a course of treatment costs less than 25 USD.
Tropicamide is an antimuscarinic drug that produces short acting mydriasis (dilation of the pupil) and cycloplegia when applied as eye drops. It is used to allow better examination of the lens, vitreous humor, and retina. Due to its relatively short duration of effect (4–8 hours), it is typically used during eye examinations such as the dilated fundus examination, but it may also be used before or after eye surgery. Cycloplegic drops are often also used to treat anterior uveitis, decreasing risk of posterior synechiae and decreasing inflammation in the anterior chamber of the eye.
...
Wikipedia